The evidence with the title 'Why did mylan hike epipen prices 400%? Because they could ' says Aug 21, 2016  ... Pharmaceutical company has a virtual monopoly on EpiPens after avoluntary recall felled their only competitor * , Sanofi 's auvi-q, over possible  ... The patient now pays about 400 % more for this advantage to receive a dollar 's worth of the lifesaving drug : EpiPens were about $57 when Mylan acquired it. 
